ResearchMETA
Re-rating path for META
Healthcare: META over 21 days — demo research by @fatima_alhariri.
Fatima Al-Hariri on META.
PhD pharmacology. I focus on PDUFA dates, trial readouts, and mispriced optionality in mid-cap biotech.
Thesis: long over 21 days. Entry locked at publication. Risk: macro shock overwhelms the single-name view.
[Demo seed content — not investment advice.]